Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: Analysis of the telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease (TRANSCEND) and the ongoing telmisartan alone and in combination with ramipril global end point trial (ONTARGET)

Circulation

Volumn 126, Issue 8, 2012, Pages 934-941

  Kappert, Kai ^a   Böhm, Michael ^c   Schmieder, Roland ^d   Schumacher, Helmut ^e   Teo, Koon ^f   Yusuf, Salim ^f   Sleight, Peter ^g   Unger, Thomas ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c SAARLAND UNIVERSITY   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f MCMASTER UNIVERSITY   (Canada)

^g JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

cardiovascular diseases; heart failure; myocardial infarction; sex; stroke

Indexed keywords

RAMIPRIL; TELMISARTAN;

ACUTE HEART INFARCTION; ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DEMOGRAPHY; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; TREATMENT OUTCOME;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RAMIPRIL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; SEX CHARACTERISTICS; SEX DISTRIBUTION; STROKE;

EID: 84865262748     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.086660     Document Type: Article

References (16)

1. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743-753. (Pubitemid 351640675)
2. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations: Monitoring Trends and Determinants in Cardiovascular Disease. Lancet. 1999;353:1547-1557. (Pubitemid 29219203)
3. Muller-Nordhorn J, Binting S, Roll S, Willich SN. An update on regional variation in cardiovascular mortality within Europe. Eur Heart J. 2008; 29:1316-1326. (Pubitemid 351768126)
4. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559. (Pubitemid 351522739)
5. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:1174-1183.
6. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, Hilbrich L, Pogue J, Schumacher H. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J. 2004; 148:52-61. (Pubitemid 38906646)
7. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153.
8. Hyvarinen M, Qiao Q, Tuomilehto J, Soderberg S, Eliasson M, Stehouwer CDA. The difference between acute coronary heart disease and ischaemic stroke risk with regard to gender and age in Finnish and Swedish populations. Int J Stroke. 2010;5:152-156.
9. Nieminen MS, Harjola VP, Hochadel M, Drexler H, Komajda M, Brutsaert D, Dickstein K, Ponikowski P, Tavazzi L, Follath F, Lopez-Sendon JL. Gender related differences in patients presenting with acute heart failure: results from EuroHeart Failure Survey II. Eur J Heart Fail. 2008;10:140-148. (Pubitemid 351221390)
10. Anand SS, Islam S, Rosengren A, Franzosi MG, Steyn K, Yusufali AH, Keltai M, Diaz R, Rangarajan S, Yusuf S. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. Eur Heart J. 2008;29:932-940. (Pubitemid 351499478)
11. Morrish NJ, Stevens LK, Fuller JH, Keen H, Jarrett RJ. Incidence of macrovascular disease in diabetes mellitus: the London cohort of the WHO Multinational Study of Vascular Disease in Diabetics. Diabetologia. 1991;34:584-589.
12. Lundberg V, Stegmayr B, Asplund K, Eliasson M, Huhtasaari F. Diabetes as a risk factor for myocardial infarction: population and gender perspectives. J Intern Med. 1997;241:485-492. (Pubitemid 27315829)
13. Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ. 2011;342:d671.
14. Brien SE, Ronksley PE, Turner BJ, Mukamal KJ, Ghali WA. Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies. BMJ. 2011;342:d636.
15. Larsson SC, Giovannucci E, Wolk A. Alcoholic beverage consumption and gastric cancer risk: a prospective population-based study in women. Int J Cancer. 2007;120:373-377. (Pubitemid 44956849)
16. Clarke CA, Purdie DM, Glaser SL. Population attributable risk of breast cancer in white women associated with immediately modifiable risk factors. BMC Cancer. 2006;6:170.